中文名称 | 英文名称 | CAS号 | 化学式 | 分子量 |
---|---|---|---|---|
—— | (1R,2R)-1-(3,4-bis(benzyloxy)phenyl)propane-1,2,3-triol | 362632-36-8 | C23H24O5 | 380.441 |
—— | (E)-3-(3,4-bis(benzyloxy)phenyl)acrylic acid | 54429-62-8 | C23H20O4 | 360.409 |
中文名称 | 英文名称 | CAS号 | 化学式 | 分子量 |
---|---|---|---|---|
(2R,3S)-5,7-二(苄氧基)-2-[3,4-二(苄氧基)苯基]-3-色满醇 | 5,7,3',4'-tetra-O-benzyl-(+)-catechin | 20728-73-8 | C43H38O6 | 650.771 |
儿茶提取物 | catechin | 7295-85-4 | C15H14O6 | 290.273 |
Among the known or suspected risk factors, inflammation plays an important role in infectious and non-infectious pathways leading to cancer. Green tea polyphenols have been associated with reducing inflammation and protection against carcinogenesis, especially in prostate cancer. While most of the research in this field, so far, has focussed on epigallocatechin-3-O-gallate only, we studied epicatechin-3-O-gallate, the second most abundant green tea polyphenol with essential therapeutic potential, to obtain a more detailed understanding of its anti-tumor and anti-inflammatory action. Furthermore, to improve the bioactivity of (−)-epicatechin-3-O-gallate, we synthesized a difluoro analogue, called (−)-5,7-difluoro-epicatechin-3-O-gallate. Both compounds reduced cell proliferation of human primary inflammatory lymphocytes in an apoptosis-specific fashion, while (−)-5,7-difluoro-epicatechin-3-O-gallate had a significantly higher activity compared to the natural product (−)-epicatechin-3-O-gallate. Treatment of low-metastatic LNCaP and high-metastatic PC-3 prostate cancer cells with (−)-epicatechin-3-O-gallate and (−)-5,7-difluoro-epicatechin-3-O-gallate demonstrated a dose-dependent inhibition of cell viability in the low micromolar range. These effects suggest that (−)-epicatechin-3-O-gallate and the more effective (−)-5,7-difluoro-epicatechin-3-O-gallate could be therapeutically used to inhibit tumorigenesis during initiation, promotion, and progression by diminishing the amount of inflammation due to a reduction of inflammatory lymphocytes. Further studies are needed to prove this in in vivo experiments.
在已知或疑似的风险因素中,炎症在导致癌症的感染和非感染途径中起着重要作用。绿茶多酚与减少炎症和防癌的关联已被证实,尤其是在前列腺癌中。尽管迄今为止,这一领域的大部分研究都集中在表没食子儿茶素-3-O-没食子酸酯上,但我们研究了表没食子儿茶素-3-O-没食子酸酯,这是第二多的绿茶多酚,具有重要的治疗潜力,以更详细地了解其抗肿瘤和抗炎作用。此外,为了提高(−)-表没食子儿茶素-3-O-没食子酸酯的生物活性,我们合成了一个二氟类似物,称为(−)-5,7-二氟-表没食子儿茶素-3-O-没食子酸酯。这两种化合物以特异性凋亡的方式减少了人类原发性炎症淋巴细胞的增殖,而(−)-5,7-二氟-表没食子儿茶素-3-O-没食子酸酯的活性明显高于天然产物(−)-表没食子儿茶素-3-O-没食子酸酯。用(−)-表没食子儿茶素-3-O-没食子酸酯和(−)-5,7-二氟-表没食子儿茶素-3-O-没食子酸酯处理低转移性LNCaP和高转移性PC-3前列腺癌细胞,显示出对细胞存活的剂量依赖性抑制在低微摩尔范围内。这些效应表明,(−)-表没食子儿茶素-3-O-没食子酸酯和更有效的(−)-5,7-二氟-表没食子儿茶素-3-O-没食子酸酯在抑制炎症淋巴细胞数量减少导致的炎症量的情况下,在癌症发生的启动、促进和进展阶段可能被用于治疗。需要进一步的研究来在体内实验证明这一点。